Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from Its StealthX™ Platform

On April 27, 2023, Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced the April 24 publication of a preclinical study in Microbiology Spectrum,  a leading peer-reviewed scientific journal of the American Society for Microbiology, highlighting the therapeutic potential of its StealthX™ exosome platform technology to develop a multivalent vaccine against the spike and nucleocapsid SARS-CoV-2 proteins. The open-access article is titled “Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins.”